Group 1 - GIC Private Limited increased its stake in Adicon Holdings (09860) by purchasing 891,500 shares at HKD 5 per share, totaling HKD 4.4575 million, bringing its total holdings to 36.8375 million shares, representing 5.07% of the company, officially triggering the takeover threshold [1] - Adicon's strategic focus on AI in medical testing has garnered significant market attention, as the company transitions its medical testing services from traditional models to intelligent and ecological approaches [1] - In December 2022, Adicon signed a cooperation agreement with Huawei Cloud to initiate a new chapter in smart healthcare powered by AI technology, showcasing its technological iteration path and forward-looking layout in AI medical innovation applications [1] Group 2 - Adicon announced plans to acquire Crown Bioscience for up to USD 204 million, which is expected to significantly enhance the company's comprehensive strength in the drug development and diagnostic value chain [1] - Jefferies Financial has issued a "Buy" rating for Adicon Holdings (09860) with a target price of HKD 12.60, citing the company's strategic layout in AI medical testing and the acquisition of Crown Bioscience as major initiatives to strengthen its position [2] - Analysts suggest that GIC's stake increase may create a demonstration effect, promoting Adicon's ecological expansion in the AI medical field and further solidifying its market position as a leading quality asset in the industry [2]
GIC举牌艾迪康控股(09860) AI医疗战略获“耐心资本”深度锚定